Group Leader/s

 

intro

The interests of our group are centered on the biology of adult stem cells or tissue-specific stem cells and their relationship with the cancer stem cells (or tumor-initiating cells) on the development of cancer, aiming to identify potential therapeutic targets to fight cancer.

We are using the mammary gland, the central nervous system and mesenchymal stem cells to answer different questions of adult stem cell biology and to compare characteristics between them.

Although cancer was envisioned for a long time as a group of cells undergoing uncontrolled growth, the recently demonstrated Cancer Stem Cell hypothesis indicates that within a tumor, a small fraction of cells, with characteristics of Stem Cells, transfer the tumorigenic properties. Suggesting that cancer therapies targeting the CSC will be more effective than current therapies. Therefore, it is of great interest to improve out knowledge of CSC biology in order to design these therapies. We participate in the development of monoclonal antibodies (mAbs) with therapeutic potential in cancer, one of them targeting neural stem cells and two targeting cancer cells that will generate intestine metastases.

 

Gema Elvira, Isabel García, Juan Gallo, Marina Benito, Paula Montesinos, Esther Holgado-Martin, Angel Ayuso-Sacido, Soledad Penadés, Manuel Desco, Augusto Silva & Jose A. Garcia-Sanz  [2014]. Detection of mouse endogenous type B astrocytes migrating towards grain lesions. Stem Cell Research. dii:10.1016/j.scr.2014.11.006

G. Elvira, B. Moreno, I. del Valle, J. A. Garcia-Sanz, M. Canillas, E. Chinarro, J.R. Jurado & A. Silva  [2012]. J Biomater Appl 2012 26: 1069

Elvira G, Garcia I, Benito M, Gallo J, Desco M, Penadés S, Garcia-Sanz JA, Silva A  [2012]. Live imaging of mouse endogenous neural progenitors migrating in response to an induced tumor. PLoS One 7(9): e44466

Diaz-Guerra E, Lillo MA, Santamaria S, Garcia-Sanz JA  [2012]. Intrinsic cues and hormones control mouse mammary epithelial tree size. FASEB journal 26:3844-3853

 

Funding

PROJECT TITLE: Hematopoietic cell development and function: novel genes regulated by signal transduction controlled translationFINANCIAL ENTITY: European Union (ERB4061PL970701) LENGHT FROM: 1998 TO: 2002 PRINCIPAL INVESTIGATOR: Hartmut Beug (co-ordinator), Enric Espel, Jose A. Garcia-Sanz, Ernst W. Müllner, Christopher G. Proud, Günter Schütz

PROJECT TITLE: Generation of a RNA profile of breast cancer tumorigenesis for genes controlled by transcription, processing and export, mRNA stability and translationFINANCIAL ENTITY: Dept. of the Army, US Army Med. Res. Acquisition Activity (DAMD17-02-1-0339) LENGHT FROM: 2002 TO: 2006 PRINCIPAL INVESTIGATOR: Jose A. Garcia-Sanz

PROJECT TITLE: Molecular Analysis of Immune responsesFINANCIAL ENTITY: Spanish Ministry of Science and Technology SAF2003-00519 LENGHT FROM: 2003 TO: 2006 PRINCIPAL INVESTIGATOR: Jose A. Garcia-Sanz

PROJECT TITLE: Molecular Analysis of Mammary Stem CellsFINANCIAL ENTITY: CSIC (CSIC/2004 2 0E 240) LENGHT FROM: 2006 TO: 2009 PRINCIPAL INVESTIGATOR: Jose A. Garcia-Sanz

PROJECT TITLE: Molecular analysis of the generation of antigen-specific CD8+ T lymphocytes with a regulatory (FoxP3+) phenotype: therapeutical applicationsFINANCIAL ENTITY: Spanish Ministry of Education and Science (SAF2006-04903) LENGHT FROM: 2006 TO: 2007 PRINCIPAL INVESTIGATOR: Jose A. Garcia-Sanz

PROJECT TITLE: Molecular analysis of the generation of antigen-specific CD8+ T lymphocytes with a regulatory (FoxP3+) phenotype: therapeutical applications FINANCIAL ENTITY: Ministerio de Educación y ciencia (SAF2007-63631)LENGHT FROM: 2007 TO: 2009 PRINCIPAL INVESTIGATOR: Jose A. Garcia-Sanz

PROJECT TITLE: Red de Terapia CelularFINANCIAL ENTITY: Instituto de Salud Carlos III (RD06/0010/1010) LENGHT FROM: 2008 TO: 2014 PRINCIPAL INVESTIGATOR: Jose A. Garcia-Sanz

PROJECT TITLE: Adult Stem Cells: cellular and molecular análisisFINANCIAL ENTITY: Ministerio de Ciencia y Tecnologia SAF2009-07974 LENGHT FROM: 2009 TO: 2012 PRINCIPAL INVESTIGATOR: Jose A. Garcia-Sanz

PROJECT TITLE: Regenerative treatment of intra-bone periodontal defects using cellular therapyFINANCIAL ENTITY: Ministerio de Sanidad y Asuntos Sociales Ensayos Clínicos no comerciales C10-095 LENGHT FROM: 2011 TO: 2014 PRINCIPAL INVESTIGATOR: Mariano Sanz AlonsoPROJECT TITLE: Soft tissue regeneration by cell therapy using gingival-derived mesenchymal stem cells implanted in a porcine derived collagen matrix

FINANCIAL ENTITY: Osteology FoundationLENGHT FROM: 2013 TO: 2015 PRINCIPAL INVESTIGATOR: Mariano Sanz Alonso

PROJECT TITLE: DEVELOPMENT of THERAPEUTIC ANTI-CCR9 ANTIBODIES FOR THE PERSONALIZED TREATMENT OF TIMORS-TERPERAN

FINANCING ENTITY: Ministerio de Economia y Competitividad/FEDER Retos Colaboracion (RTC-2015-3786-1)

Principal Investigator: Jose A. Garcia-Sanz

LENGTH: from 2015 to 2018

PROJECT TITLE: Immunotherapiy with a monoclonal antibody against high grade brain tumors-Gliomatherapy

FINANCING ENTITY: Ministerio de Economia y Competitividad/FEDER Retos Colaboracion (RTC-2015-3846-1)

Principal Investigator: Jose A. Garcia-Sanz

LENGTH: from 2015 to 2018

 

More info

Patent 1:

Inventors: L. Carramolino, S. Chamorro, A. Franco, Jose A. Garcia-Sanz, J. Gutierrez, L. Kremer, C. Martinez-A. and M. Vela.

Antibodies against CCR9 and Applications Thereof. Application Form Number: EP13382469.8, Priority Country: EU. Priority date: 25/11/2013. Holder Entity: CSIC. Licensed to: SunRock Pharmaceuticals S.L.

Patent 2:

Inventors: Augusto Silva Gonzalez (Althia Health SL) and Jose A. Garcia-Sanz (CIB-CSIC)

Monoclonal Antibody For The Diagnosis, Treatment And/Or Prevention Of Brain Tumors And Brain Lesions

Application form no: EP14382545.3 Priority Country: EU Priority date: 10/12/2014. Holder Entity: Althia Health, S.L. and CSIC